Prediction of clinical outcomes using B-type natriuretic peptides in the general population: A systematic review

Heart Failure Reviews

Volumn 19, Issue 4, 2014, Pages 541-551

  Don Wauchope, Andrew C ^a   Santaguida, Pasqualina L ^a   McKelvie, Robert ^a   Brown, Judy A ^a   Oremus, Mark ^a   Ali, Usman ^a   Bustamam, Amy ^a   Sohel, Nazmul ^a   Hill, Stephen A ^a   Booth, Ronald A ^b   Balion, Cynthia ^a   Raina, Parminder ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Discrimination statistics; General population; Natriuretic peptide; Prognosis; Systematic review

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE;

ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; MORBIDITY; OUTCOME ASSESSMENT; POPULATION RISK; PREDICTION; PROGNOSIS; PROTEIN DETERMINATION; RISK ASSESSMENT; SYSTEMATIC REVIEW; BLOOD; DISEASE MANAGEMENT; HEALTH; SURVIVAL RATE;

DISEASE MANAGEMENT; GLOBAL HEALTH; HEART FAILURE; HUMANS; MORBIDITY; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; SURVIVAL RATE;

EID: 84906343243     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-014-9446-7     Document Type: Article

References (24)

1. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA et al (2010) 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults. J Am Coll Cardiol 56:e50-e103. doi:10.1016/j.jacc.2010.09. 001
2. Daniels LB, Laughlin GA, Clopton P, Maisel AS, Barrett-Connor E (2008) Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study. J Am Coll Cardiol 52:450-459. doi:10.1016/j.jacc.2008.04.033 (Pubitemid 352040812)
3. Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A et al (2008) Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 358:2107-2116. doi:10.1056/NEJMoa0707064 (Pubitemid 351679597)
4. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engstrom G et al (2009) Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 302:49-57. doi:10.1001/jama.2009. 943
5. Blankenberg S, Zeller T, Saarela O, Havulinna AS, Kee F, Tunstall-Pedoe H et al (2010) Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 121:2388-2397. doi:10.1161/CIRCULATIONAHA.109.901413
6. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K et al (2007) N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J 28:1374-1381. doi:10.1093/eurheartj/ehl448 (Pubitemid 47355969)
7. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D et al (2009) B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circ Cardiovasc Qual Outcomes 120:2177-2187. doi:10.1161/CIRCULATIONAHA.109.884866
8. Balion C, Don-Wauchope A, Hill S, Santaguida PL, Booth R, Brown JA, Oremus M, Ali U, Bustamam A, Sohel N, McKelvie R, Raina P (2013) Use of natriuretic peptide measurement in the management of heart failure. Comparative Effectiveness Reviews, No. 126. 2013. AHRQ Publication No. 13(14)-EHC118-EF. www.effectivehealthcare.ahrq.gov/reports/final.cfm
9. Alehagen U, Dahlström U, Rehfeld JF, Goetze JP (2011) Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. JAMA 305:2088-2095. doi:10.1001/jama.2011.666
10. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K et al (2008) Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex. J Hypertens 26:26-34. doi:10.1097/HJH.0b013e3282f18301 (Pubitemid 350294846)
11. Linssen GC, Bakker SJ, Voors AA, Gansevoort RT, Hillege HL, de Jong PE et al (2010) N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur Heart J 31:120-127.doi:10.1093/eurheartj/ehp420
12. van Hateren KJ, Alkhalaf A, Kleefstra N, Groenier KH, de Jong PE, de Zeeuw D et al (2012) Comparison of midregional pro-Atype natriuretic peptide and the N-terminal pro-B-type natriuretic peptide for predicting mortality and cardiovascular events. Clin Chem 58:293-297. doi:10.1373/clinchem.2011.166348
13. Hayden JA, Côté P, Bombardier C (2006) Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 144:427-437. doi:10.7326/0003-4819-144-6-200603210-00010 (Pubitemid 46768164)
14. Chisalita SI, Dahlström U, Arnqvist HJ, Alehagen U (2011) Increased IGF1 levels in relation to heart failure and cardiovascular mortality in an elderly population: impact of ACE inhibitors. Eur J Endocrinol 165:891-898. doi:10.1530/EJE-11-0584
15. Patton KK, Sotoodehnia N, deFilippi C, Siscovick DS, Gottdiener JS, Kronmal RA (2011) N-terminal pro-B-type natriuretic peptide is associated with sudden cardiac death risk: the Cardiovascular Health Study. Heart Rhythm 8:228-233. doi:10.1016/j.hrthm.2010.10.038
16. Smith JG, Newton-Cheh C, Almgren P, Struck J, Morgenthaler NG, Bergmann A et al (2010) Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol 56:1712-1719. doi:10.1016/j.jacc.2010.05.049
17. Vaes B, de Ruijter W, Degryse J, Westendorp RG, Gussekloo J (2009) Clinical relevance of a raised plasma N-terminal pro-brain natriuretic peptide level in a population-based cohort of nonagenarians. J Am Geriatr Soc 57:823-829. doi:10.1111/j.1532-5415.2009.02218.x
18. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62:e147-e239. doi:10.1016/j.jacc.2013.05.019
19. Schmitter D, Cotter G, Voors AA (2014) Clinical use of novel biomarkers in heart failure: towards personalized medicine. Heart Fail Rev 19:369-381. doi:10.1007/s10741-013-9396-5
20. Metra M, Ponikowski P, Dickstein K, McMurray JJV, Gavazzi A, Bergh C-H et al (2007) Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 9:684-694. doi:10.1016/j.ejheart.2007. 04.003 (Pubitemid 46705572)
21. Arcopinto M, Bobbio E, Bossone E, Perrone-Filardi P, Napoli R, Sacca L et al (2013) The GH/IGF-1 axis in chronic heart failure. Endocr Metab Immune Disord Drug Targets 13:76-91
22. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS et al (2009) Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circ Cardiovasc Qual Outcomes 119:2408-2416. doi:10.1161/CIRCULATIONAHA.109.192278
23. Payne RA (2012) Cardiovascular risk. Br J Clin Pharmacol 74:396-410. doi:10.1111/j.1365-2125.2012.04219.x
24. Rosenberg J, Schou M, Gustafsson F, Badskjaer J, Hildebrandt P (2009) Prognostic threshold levels of NT-proBNP testing in primary care. Eur Heart J 30:66-73. doi:10.1093/eurheartj/ehn525